- Digitalis glycosides were associated with a lower risk of cardiovascular death or first worsening heart failure event (41% vs 45%; HR, 0.85).
- Worsening heart failure events occurred less frequently with digitalis glycosides than placebo (26% vs 33%; HR, 0.75).
- Researchers found no statistically significant reduction in cardiovascular death or all-cause mortality with digitalis glycoside therapy.
- The analysis included the DIG, DIGIT-HF, and DECISION trials and found no statistically significant heterogeneity by treatment era or type of digitalis glycoside.
- Researchers suggested digitalis glycosides may serve as additional therapy to reduce worsening heart failure events in patients with HFmrEF or HFrEF.
Digitalis Reduces HF Events but Not Mortality
Conexiant
May 12, 2026
